Jeenjoo Kang
Founder at Appia Bio, Inc.
Profile
JeenJoo S Kang is the founder and CEO of Appia Bio, Inc. founded in 2020.
She is currently serving as a member of the Board of Directors at Escient Pharmaceuticals, Inc. Dr. Kang has previously worked as a Director at Exonics Therapeutics, Inc. from 2017 to 2020, as an Independent Director at Tenaya Therapeutics, Inc. from 2016 to 2021, and as a Venture Partner at The Column Group LLC from 2020 to 2022.
Dr. Kang completed her undergraduate studies at Harvard University and received her doctorate from the California Institute of Technology in 2015.
Jeenjoo Kang active positions
Companies | Position | Start |
---|---|---|
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Founder | 2019-12-31 |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Director/Board Member | - |
Former positions of Jeenjoo Kang
Companies | Position | End |
---|---|---|
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Analyst | 2016-12-31 |
TENAYA THERAPEUTICS, INC. | Director/Board Member | 2021-11-16 |
Exonics Therapeutics, Inc.
Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Director/Board Member | 2020-08-29 |
Training of Jeenjoo Kang
Harvard University | Undergraduate Degree |
California Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TENAYA THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
Exonics Therapeutics, Inc.
Exonics Therapeutics, Inc. BiotechnologyHealth Technology Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jeenjoo Kang